WO2009044787A1 - Remède contre une maladie de rupture de tendon comprenant de la ténomoduline en tant qu'ingrédient actif - Google Patents

Remède contre une maladie de rupture de tendon comprenant de la ténomoduline en tant qu'ingrédient actif Download PDF

Info

Publication number
WO2009044787A1
WO2009044787A1 PCT/JP2008/067881 JP2008067881W WO2009044787A1 WO 2009044787 A1 WO2009044787 A1 WO 2009044787A1 JP 2008067881 W JP2008067881 W JP 2008067881W WO 2009044787 A1 WO2009044787 A1 WO 2009044787A1
Authority
WO
WIPO (PCT)
Prior art keywords
tenomodulin
disease
remedy
active ingredient
tendon rupture
Prior art date
Application number
PCT/JP2008/067881
Other languages
English (en)
Japanese (ja)
Inventor
Keiichi Fukuda
Yuji Hiraki
Chisa Shukunami
Original Assignee
Keiichi Fukuda
Yuji Hiraki
Chisa Shukunami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keiichi Fukuda, Yuji Hiraki, Chisa Shukunami filed Critical Keiichi Fukuda
Priority to JP2009536074A priority Critical patent/JPWO2009044787A1/ja
Publication of WO2009044787A1 publication Critical patent/WO2009044787A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

Il est clarifié que l'inhibition de l'expression ou de la fonction de la ténomoduline induit une maladie apparentée à la rupture d'un tendon tel que CTC. Il est attendu que la protéine ténomoduline ou une substance capable d'activer l'expression ou la fonction de cette protéine est efficace de manière thérapeutique sur une maladie de rupture de tendon.
PCT/JP2008/067881 2007-10-02 2008-10-02 Remède contre une maladie de rupture de tendon comprenant de la ténomoduline en tant qu'ingrédient actif WO2009044787A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009536074A JPWO2009044787A1 (ja) 2007-10-02 2008-10-02 テノモジュリンを有効成分とする腱断裂性疾患治療剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007258357 2007-10-02
JP2007-258357 2007-10-02

Publications (1)

Publication Number Publication Date
WO2009044787A1 true WO2009044787A1 (fr) 2009-04-09

Family

ID=40526211

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/067881 WO2009044787A1 (fr) 2007-10-02 2008-10-02 Remède contre une maladie de rupture de tendon comprenant de la ténomoduline en tant qu'ingrédient actif

Country Status (2)

Country Link
JP (1) JPWO2009044787A1 (fr)
WO (1) WO2009044787A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014125482A (ja) * 2012-12-27 2014-07-07 Hayashikane Sangyo Kk 腱および靱帯機能改善剤ならびにこれを含む医薬組成物、食品および飼料

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KIMURA,N. ET AL.: "The anti-angiogenic factor, tenomodulin, has a pivotal role in maintaining avascularity of chordae tendineae cordis", CIRCULATION, vol. 16, no. SUPPL., 16 October 2007 (2007-10-16), pages 234 *
NARITAKA KIMURA ET AL.: "Kensaku Danretsu Hassho no Mechanism - Kekkan Shinsei tono Kanrensei ni Tsuite", GENERAL THORACIC AND CARDIOVASCULAR SURGERY, vol. 55, 18 September 2007 (2007-09-18), pages 431 *
OSHIMA,Y. ET AL.: "Anti-angiogenic action of the C-terminal domain of tenomodulin that shares homology with chondromodulin-I", JOURNAL OF CELL SCIENCE, vol. 117, no. 13, 2004, pages 2731 - 2744 *
PETERSEN,W. ET AL.: "Expression of VEGFR-1 and VEGFR-2 in degenerative Achilles tendons", CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, no. 420, 2004, pages 286 - 91 *
SHUKUNAMI,C. ET AL.: "Molecular Cloning of tenomodulin, a Novel Chondromodulin-I Related Gene", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 280, no. 5, 2001, pages 1323 - 1327 *
YOSHIOKA,M. ET AL.: "Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis", NATURE MEDICINE, vol. 12, no. 10, 2006, pages 1151 - 1159 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014125482A (ja) * 2012-12-27 2014-07-07 Hayashikane Sangyo Kk 腱および靱帯機能改善剤ならびにこれを含む医薬組成物、食品および飼料

Also Published As

Publication number Publication date
JPWO2009044787A1 (ja) 2011-02-10

Similar Documents

Publication Publication Date Title
WO2009068689A3 (fr) Combinaison d'inhibiteurs de protéine tyrosine phosphatase et d'hormone de croissance humaine pour le traitement d'une atrophie musculaire et de troubles associés
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
CL2007003802A1 (es) Compuestos derivados de piperidina, inhibidores de la sintasa de acidos grasos; procedimiento de preparacion de dichos compuestos; y su uso para tratar la obesidad o el sobrepeso.
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
WO2007038459A3 (fr) Composes de carboxyamine et leurs methodes d'utilisation
NL1028086A1 (nl) Sulfonamidederivaten voor de behandeling van ziekten.
CL2008000594A1 (es) Uso de compuestos derivados de heterociclos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad arterial coronaria entre otras enfermedades.
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
WO2007025613A3 (fr) Utilisation de composes se liant au recepteur sigma pour traiter la douleur associee au diabete
NL1028087A1 (nl) Sulfonamiderivaten voor de behandeling van ziekten.
WO2008115469A3 (fr) Rôle de la signalisation par hérisson dans l'athérosclérose et les maladies cardiovasculaires
BRPI0819864A2 (pt) composição farmacêutica destinada ao tratamento de doenças relacionadas à obesidade que compreende um conjugado peptídico insulinotrópico
GT200600109A (es) Derivados de acido pirimidincarboxilico y su uso
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
CL2007002974A1 (es) Compuestos derivados de benzoimidazol; composicion farmaceutica; y uso para el tratamiento de trastornos asociados con dgat1.
WO2008076954A3 (fr) Composés hétérocycliques et procédés d'utilisation de ceux-ci
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
NL1028599A1 (nl) Verbindingen voor de behandeling van ziekten.
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
CL2007003480A1 (es) Compuestos derivados de tiazolo[5,4-c]piridin-4-ona sustituida; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento o prevencion de enfermedades relacionadas con la obesidad, como trastornos de la alimentacion, diab
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas
IL192415A0 (en) Pharmaceutical composition for the treatment of nail diseases
WO2012119046A3 (fr) Composés hétérocycliques pour l'inhibition de la kinase de domaine pas (pask)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08835367

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009536074

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08835367

Country of ref document: EP

Kind code of ref document: A1